Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,396 shares of the medical instruments supplier’s stock after acquiring an additional 334 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Becton, Dickinson and Company were worth $6,436,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $25,000. Fortitude Family Office LLC bought a new position in Becton, Dickinson and Company during the 4th quarter valued at $35,000. Venturi Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 552.0% during the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 138 shares during the last quarter. Arlington Trust Co LLC acquired a new position in Becton, Dickinson and Company during the 4th quarter worth $41,000. Finally, MCF Advisors LLC increased its position in shares of Becton, Dickinson and Company by 51.4% in the 4th quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock worth $52,000 after purchasing an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $234.36 on Wednesday. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average price is $239.72 and its two-hundred day moving average price is $241.79. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The stock has a market capitalization of $67.71 billion, a P/E ratio of 55.54, a P/E/G ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. During the same period in the prior year, the firm earned $2.98 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Barclays lifted their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James lifted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.